On August 20, 2010
Drugmaker Elan Tempts the SEC to Investigate Its Tangled, Undisclosed Deals
Elan appears to be tempting the SEC to investigate after it was revealed that the company didn’t disclose it bought an epilepsy drug from a linked company for $700,000.
No tags for this post.
0 Comments